Results 81 to 90 of about 1,448,905 (180)
AustrAIHANZ – consensus guidelines on the investigation and management of autoimmune haemolytic anaemia in Australia and New Zealand
Internal Medicine Journal, EarlyView.Abstract
Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...Philip Choi, Eileen Merriman, Ashwini Bennett, Anoop Enjeti, Chee Wee Tan, Isaac Goncalves, Danny Hsu, Jun Yen Ng, Anastazia Keegan, Robert Bird +9 morewiley +1 more sourcePathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria
Journal of the European Academy of Dermatology and Venereology, EarlyView.This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira +2 morewiley +1 more sourceManagement of chronic urticaria: Current status and future prospect
Journal of the European Academy of Dermatology and Venereology, EarlyView.Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.Andaç Salman, Mona Al‐Ahmad, Maryam Al‐Nesf, Chia‐Yu Chu, Luis Felipe Ensina, Ana M. Gimenez‐Arnau, Margarida Gonçalo, Clive Grattan, Michihiro Hide, Pavel Kolkhir, Martin Metz, Iman Nasr, Romi Saini, Simon Francis Thomsen, Torsten Zuberbier, Emek Kocaturk +15 morewiley +1 more sourceTargeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab
Journal of the European Academy of Dermatology and Venereology, EarlyView.Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...Rhea Ahuja, Dedee Murrellwiley +1 more sourceUVI5008: the first reversible, non-covalent Bruton’s tyrosine kinase epi-inhibitor for B-cell malignancies
Journal of Hematology & OncologyBackground Chronic lymphocytic leukemia (CLL) can still be a therapeutic challenge; notwithstanding substantial progress in therapeutic approaches with small molecule inhibitors, the emergence of inhibitor resistance and suboptimal long-term outcomes ...Carmela Dell’Aversana, G. Sgueglia, C. Massaro, U. Perricone, F. Sarno, W. L. Megchelenbrink, M. Conte, V. Carafa, A. Campanella, M. Frenquelli, J. Bordini, P. Ghia, V. B. Petrizzi, R. Alvarez, D. Nappi, F. Chiurazzi, F. P. Tambaro, W. G. Wierda, A. R. de Lera, Lucia Altucci +19 moredoaj +1 more sourceReactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies
Transplant Infectious Disease, EarlyView.In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...Alisse Hannaford, Zoe Swank, Simon D. van Haren, Natalie Izaguirre, Caitlin Syphurs, Zhou Lan, Bridget Yates, Urwah Kanwal, Grace Valentine, Ella Woehl, David Regan, Hannah Levine, Alexandra Tong, Maria Shehata, Fathia Oladipupo, Colleen Sedney, Kevin Ryff, Sanya Thomas, Joann Diray‐Arce, Xiaofang Li, Kimberly A. Dufresne, Lindsey A. Parisi, Aidan Eustace, Louise Hansen, David R. Walt, Ofer Levy, Amar Kelkar, Robert J. Soiffer, Vincent T. Ho, Lindsey R. Baden, Nicolas C. Issa, Ann E. Woolley, Amy C. Sherman +32 morewiley +1 more sourceDiscovery of Branebrutinib
(BMS-986195): A Strategy
for Identifying a Highly Potent and Selective Covalent Inhibitor Providing
Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)
, 2019 Bruton’s
tyrosine kinase (BTK), a non-receptor tyrosine
kinase, is a member of the Tec family of kinases and is essential
for B cell receptor (BCR) mediated signaling.Douglas G. Batt (1622293), Ling Li (38566), Naiyu Zheng (6251045), Yifan Zhang (119570), Rodney Vickery (3079041), Celia D’Arienzo (1601488), Rulin Zhao (1565887), Michael A. Wallace (6171962), Robin Moore (4805118), Claudine Pulicicchio (2296048), Daniel Smith (6120), Luisa Salter-Cid (1429873), Kim W. McIntyre (1429864), Richard Rampulla (1601455), Paul A. Elzinga (1436380), Scott H. Watterson (2381527), Aberra Fura (1436362), Mark A. Pattoli (2381518), Zheng Yang (264955), Tracy L. Taylor (1429903), John E. Macor (1399363), Qingjie Liu (1376271), Joseph A. Tino (2306992), Arvind Mathur (144120), Ian M. Catlett (6528242), Charu Chaudhry (1655965), Myra Beaudoin Bertrand (2407588), Qian Ruan (2141782), Jianqing Li (523126), James R. Burke (258157), Jun Dai (435229), Percy H. Carter (1355331), Kathleen M. Gillooly (2459560), Elizabeth Heimrich (3124926), Andrew J. Tebben (1436383), Richard A. Westhouse (1601467), Matt Pokross (1399390), Mary T. Obermeier (1436389), Stacey Skala (2517658), Michael A. Galella (2065051), Lihong Cheng (3124929), Lorell Discenza (2332528), Alban Allentoff (1898476) +42 morecore +1 more sourceReal‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Background
Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...John M. Burke, Ira Zackon, Yunfei Wang, Kathleen M. Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Siyang Leng, Inkyu Kim, Diana Chirovsky, Enrico de Nigris +10 morewiley +1 more sourceBruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma
, 2018 Aberrant activation of anaplastic lymphoma kinase (ALK) can cause sporadic and familial neuroblastoma. Using a proteomics approach, we identified Bruton’s tyrosine kinase (BTK) as a novel ALK interaction partner, and the physical interaction was ...Chan, Wai Yee, Lars Rönnstrand, Bo Feng, Li, Tianfeng, Zhao, Hui, Li, Tianfeng,, Chan, Sun On,, Tian, Ruijun, Yi Deng, Julhash U. Kazi, Rönnstrand, Lars, Sun On Chan, Shi, Yu,, Zou, Lin, Ruijun Tian, Deng, Yi,, Chan, Wai Yee,, Tian, Ruijun,, Kazi, Julhash U., Deng, Yi, Feng, Bo, Hui Zhao, Tianfeng Li, Zou, Lin,, Feng, Bo,, Sun, Jianmin,, Jianmin Sun, Rönnstrand, Lars,, Yu Shi, Chen, Yonglong,, Chen, Yonglong, Wai Yee Chan, Lin Zou, Yonglong Chen, Chan, Sun On, Kazi, Julhash U.,, Sun, Jianmin, Lund University., Shi, Yu, Zhao, Hui, +39 morecore +1 more sourceAtrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods
We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.Andrea Visentin, Enrica Antonia Martino, Alessandro Cellini, Francesco Angotzi, Annalisa Pitino, Andrea Duminuco, Ernesto Vigna, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Anna Maria Frustaci, Marcello Riva, Sara Pepe, Adalberto Ibatici, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Francesco Malaspina, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Fraticelli, Candida Vitale, Azzurra Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozella, Luigi Malandruccolo, Marzia Varettoni, Lucia Morello, Giuseppe Pietrantuono, Esmeralda Conte, Martina Cantelli, Roberta Murru, Daniele Caracciolo, Enrico Derenzini, Valentina Di Martina, Roberto Marasca, Maria Ilaria Del Principe, Amalia Figuera, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Nicola Amodio, Alessandro Allegra, Vittorio Del Fabro, Paolo Fiumara, Luca Scalise, Fabio Stagno, Giorgio Tona, Pellegrino Musto, Laura Caruso, Arcangelo Liso, Alessandra Tedeschi, Gianluca Gaidano, Francesca Romana Mauro, Giovanni Tripepi, Fortunato Morabito, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Valter Gattei, Livio Trentin, Massimo Gentile +92 morewiley +1 more source